U.S.A’s Food and Drug Administration
It is a desire for all people to have a process that can speed up the available drugs that can be used to treat serious illnesses, particularly when the drugs are considered the first accessible treatment or they have advantages over existing therapies. One of the successful and distinct approaches the U.S.A’s Food and Drug Administration has established is the ‘fast track’. This is a process intended to ease the development as well as accelerate drug reviews to treat severe diseases and fulfill the unmet medical needs. Its main aim is to get important new drugs to the patients promptly. Congress initially formed the first track approach in legislation planned to address various conditions that are termed to be serious although the term is currently used more liberally than what was intended initially.
The primary purpose as to why the FDA chose a fast track as one of their main approaches was the intention to have drugs that can treat severe or life-threatening diseases. However, in evaluating which condition is dangerous is a notion of judgment, but ideally, it is based on whether the drug will pose any effect on factors like daily functioning, survival or the probability of the illness progressing from a less severe state to a more severe state if left untreated (Marshall & Baylor, 2011). This approach addresses the desire to approve treatment for a vast range of conditions including Alzheimer’s, AIDS, depression, epilepsy, diabetes, heart failure, and cancer.
A drug company manufacturing a new therapy that is granted the fast track position may be permitted to more regular written communications and meetings with the FDA to stay on top of developmental plans of the drug, form data necessities as well as clear-up the study criteria details. Such meetings involve pre- IND, end of phase 1 and phase 2 meetings. This review can also benefit the rolling review procedure whereby parts of the application can be handed in for investigation before handing in the complete application (Considine et al., 2010). In other words, the pharmaceutical company is permitted to submit its biologic license application or new drug application pieces for review by FDA as once they get ready rather than having to hold on until the whole application is available for consideration as a whole, which is the usual case.
A pharmaceutical product of the fast track therapy may be regarded eligible for accelerated approval and priority review if it gets support from the clinical data during NDA, BLA, or efficiency supplement submissions (Marshall & Baylor, 2011). Once FDA determines that the product of fast tract therapy could be useful after conducting a preliminary evaluation of clinical data submitted by a sponsor, the agency might consider reviewing some section of the marketing application before final submission of the complete application by the sponsor.
The benefit of having this approach in practice is that it will allow an application to be submitted at any given period during the drug manufacturing process as well as can make use of clinical or preclinical data to demonstrate the ability to address medical desire that is unmet. It is expected that the FDA will respond to the submitted application within 60 days on the basis that the drug fulfills the medical need that is unmet in severe disease. Once the drug is granted the fast track designation, frequent and early communications between the drug company and the FDA is encouraged all through the drug manufacturing and review stages (Thaul, 2012). The constant communication guarantees that issues and questions are resolved in time, usually resulting in earlier drug approval as well as access by the patients.
In summary, it is expected that the fast track drug demonstrates additional advantages over the existing medical treatments like demonstrating superior effectiveness, preventing adverse side effects of the already provided treatments, improving diagnosis of a severe illness, lowering the clinically significant toxicity of current medications and addressing the anticipated public health desire. Through this, harsh medical conditions that may result in ultimate deaths would be prevented or reduced.